Oulu, Finland 11th December 2014

Paras Biopharmaceuticals Finland Oy, a Finnish company based in Oulu has been recognized by Frost & Sullivan with the “2014 European Biopharmaceuticals Technology Innovation Leadership Award” for biopharmaceutical technology development.

Paras Biopharmaceuticals has built a robust portfolio of proprietary technologies for the production of therapeutic biomedicines for osteoporosis and diabetes. The Finnish company has developed innovative solutions for the effective and economic production of recombinant therapeutics.

Each year, Frost & Sullivan presents the Award for Technology Innovation Leadership (Europe) to the company that has demonstrated uniqueness in developing and leveraging new technologies, which significantly impacts both the functionality and the customer value of new products and applications. The award lauds the high R&D quality towards innovation, its relevance to the industry and the positive impact on brand perception.

Paras Biopharmaceuticals has successfully developed three proprietary manufacturing technologies: Diabrid® Technology, NobleCleav® Technology and Biomultifold® Microbial High Expression Technology for the development of several biopharma active pharmaceuticals ingredients (APIs), targeting therapeutic areas such as osteoporosis, rheumatoid arthritis, metabolic disorders (diabetes), and oncology.

Diabrid® Technology works as a critical enabler for achieving the correct target product, NobleCleav® Technology facilitates the high-level production of authentic biologics by combining specificity and activity of processing of recombinant therapeutic peptides and proteins, while the Biomultifold® Microbial High Expression Technology helps to achieve expression levels of multigrams of therapeutic proteins per litre of fermentation using E.coli.

“In a time of widespread economic austerity, demand for access to affordable healthcare is greater than ever” says Dr. Hans Soderlund, Director of Global Strategic Alliance at Paras Biopharmaceuticals. “This award by Frost & Sullivan recognises Paras Biopharmaceuticals’ hard work and commitment in developing more economical and efficient technologies for the production of biosimilars and noble biologics.”

“Paras Biopharmaceuticals has developed proprietary expression vectors based on the most optimum genetic codes selected for each amino acid of the therapeutic,” said Frost & Sullivan Senior Research Analyst Aiswariya Chidambaram. “Genes are coupled with suitable Diabrid® partners to achieve a unique combination of therapeutic proteins and peptides.”

“The company not only possesses exceptional process development skills to achieve the highest levels of protein expression, but also has extensive experience in protein purification,” noted Chidambaram. “Its core strengths, ranging from media selection and development, optimization of process parameters, screening of resins to minimizing aggregation concepts in purification have earned the company a reputation for being an important innovator in biopharmaceuticals.”

About Paras Biopharmaceuticals

Paras Biopharmaceuticals Finland Oy is an acclaimed enabler of biopharmaceutical manufacturing technologies for biosimilars and long therapeutic peptides. Paras’ state-of-the-art production set-up facilitates scale-up technologies and products for clinical and commercial manufacturing.

Paras’ work revolves around two main streams

• Biosimilars comprised of osteoporosis recombinant Teriparatide, analog insulin and therapeutic fragment of monoclonal antibodies
• High value recombinant enzymes such as Enterokinase (and other enzymes in pipeline).

About Frost & Sullivan

Frost & Sullivan is a Growth Partnership Company that works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. Its Growth Partnership supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure. For more than 50 years, Frost & Sullivan have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community.

Paras Biopharmaceuticals Finland Oy
Oulu, Finland 

Dr Mark Jackson – Research Associate and Company Administration
Kiviharjunlenkki 2, Oulu, FI-90220, Finland
Phone: +358 442905993
E-Mail: mark.jackson@parasbiopharma.com
Website: www.parasbiopharma.com

Paras Biopharmaceuticals Finland Oy Selected as First Finnish Company to Present at Cavendish Global Health Impact Forum

Paras Biopharmaceuticals Finland Oy, an upcoming biopharmaceutical manufacturing company for biosimilars and therapeutic peptides, announced today that it has been selected to present at the Cavendish Global Health Impact Forum taking place 10th - 14th May in La Jolla, California, USA. The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. Cavendish Impact Forums are hosted by leading institutions around the world including The University of California San Diego, The J. Craig Venter Institute, The Scripps Research Institute, The Sanford-Burnham Medical Research Institute, The Sanford Consortium for Regenerative Medicine, and The Institute of the Americas.

Michael Moffat, Cavendish co-founder and Chief Executive Officer explains, “The theme of our La Jolla, California Forum is a ‘Celebration of Philanthropy, Impact Investing and Innovation that is Changing the World.’ With the help of our expert advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence. The quality and originality of Paras Biopharmaceuticals’ technologies (Diabrid® Technology, NobleCleav® Technolgy and Biomultifold® Microbial High Expression Technolgy) and scientific insights for the development of affordable biologics allows them to make a major contribution in targeting therapeutic areas such as osteoporosis, rheumatoid arthritis, metabolic disorders (diabetes) and oncology.

“We are honoured to be selected as the first Finnish company (and only the second company in the Nordic region) to present at this unique event. Recognition of our efforts for the effective production of recombinant therapeutics to provide affordable healthcare affecting populations around the world,” said Dr. Hans Soderlund, Director of Global Strategic Alliance at Paras Biopharmaceuticals.

“In a time of widespread economic austerity and increased pressure on Governments’ health budgets, demand for access to affordable healthcare is greater than ever. We welcome the opportunity to interact with many of the world’s most accomplished scientists, thought-leaders and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people around the world,” said Dr Ashesh Kumar, Director of Biologics and Licensing at Paras Biopharmaceuticals. 

About Paras Biopharmaceuticals

(http://www.parasbiopharma.com)

Based in Oulu, Finland, Paras Biopharmaceuticals is an award winning, privately-held Finnish company focused on developing biopharmaceutical manufacturing technologies for biosimilars and long therapeutic peptides. Our facilities in Finland are dedicated to the development, scale-up and production of recombinant products for osteoporosis, rheumatoid arthritis, metabolic disorders (diabetes) and oncology.

About Cavendish Global

(http://cavendishglobal.com)

Cavendish Global consists of leading family offices and foundations from around the world with combined assets of over $190 billion who share a passion for pro-social endeavours within health and the life sciences. The Cavendish Global Health Impact Forum provides family offices with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing.  The Forum is also an opportunity for family offices to champion and share information on projects and organizations, which they are passionate about with other family offices from around the world. A unique gathering of leading family offices, Cavendish Impact Forums take place three times each year; the next Forum is being co-hosted at leading research institutions of the community of La Jolla, California.

Paras Biopharmaceuticals Finland Oy - www.parasbiopharma.com
Oulu, Finland   
Dr Mark Jackson - mark.jackson@parasbiopharma.com
+358 442905993
Kiviharjunlenkki 2, Oulu, FI-90220, Finland